Rare Partners is a non profit company devoted to the development of new therapies and diagnostics in the field of rare diseases.
The Profits of Nonprofit
The surprising results when drug development and altruism collide. [TheScientist]
Rare Partners announces a three parties alliance for the use of rapamycin in thalassemic patients, based on the research carried out by Professor Roberto Gambari and coworkers at the University of Ferrara.
Rare Partners and Fondazione Umberto Di Mario signed an agreement in the field of type 1 diabetes.
